



### **PROGRAMME ONLINE**

#### **Dear Ladies and Gentlemen, Dear Colleagues**

May we draw your attention to the high quality **programme** of the **EUFEMED online Conference 2021.** The programme with its interesting presentations guarantees an exciting conference, also on a digital level. Give yourself the opportunity to exchange know-how with a focus on the following topics:

- How to better prepare European early medicines development for future pandemics
- Technology support to reduce the risks of pandemic effects on Phase1/2 trial performance
- OXFORD Debate Do we really need placebo in single ascending dose studies?
- Trends in clinical trial designs
- Regulatory experiences with COVID-19 vaccine authorisations
- updates from researchers and service providers on particularly relevant innovations in early medicines development and on exchange of own experiences with colleagues in parallel break-out sessions
- Poster Presentations

In addition, we offer our long-term **industry partners** an interactive parallel track with their own scientific and methodological presentations. Further information to follow separately.

The detailed programme is published on the Conference Webpage.

We thank for the commitment of all **speakers** especially from the authorities:

- European Medicines Agency EMA
- Federal agency for medicines and health products FDA
- Federal Institute for Drugs and Medical Devices BfArM
- Medicines and Healthcare Products Regulatory Agency MHRA
- Ministry of Health of the Russian Federation

# Guide me to the programme now

We look forward to your registration, starting Today 22/2/2021, for our EUFEMED Conference 2021!

#### With kind regards

#### The board of AFPT-Le Club Phase 1 on behalf of

Yves Donazzolo

President of EUFEMED info@eufemed.eu

\_\_\_\_\_

Share our interests and goals in furthering early medicines development in Europe! European Federation for Exploratory Medicines Development - Read our Privacy Policy.

## AFPT – Le Club Phase 1

is a founding member of

